EyeGate begins ocular drug treatment trial; Stanford debuts wireless, self-propelled delivery device;

> EyeGate Pharma is enrolling patients for a Phase I clinical study evaluating EGP-437 in patients with anterior scleritis, using the company's ocular drug delivery system that wields a low-level electrical current to carry the drug to its target. Release

> Ikaria says it enrolled its last patient 6 weeks early for a pivotal Phase III trial investigating inhaled nitric oxide in premature infants with bronchopulmonary dysplasia. The trial began in December 2009. Release

> Deakin University in Australia, working with The Energy and Resources Institute, is launching a nanobiotechnology center that will focus, in part, on biomedical research, The Times of India reports. Story

> Ada Poon, an assistant professor at the Stanford School of Engineering, has developed a wirelessly powered, self-propelled device small enough to move through the bloodstream to conduct diagnostics, perform surgery or deliver drugs. Release

> OPKO Health has acquired the rights to BioZone's drug delivery platforms in order to improve drug solubility for its own compounds and manufacture the treatments more efficiently and cheaply. Neither side disclosed financial terms. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.